BioInvent and Transgene and report positive BT-001 data
Tumour treatment among all phase 1a cohorts in were concluded with no safety concerns
Read More
Tag: bt-001
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
